论文部分内容阅读
培哚普利(Perindopril,商品名Acertil)系不含巯基的新型血管紧张素转换酶抑制剂。本文旨在评价本品用于治疗我国高血压病患者的临床疗效和耐受性。1 资料与方法①病例选择:按WHO(1978)标准诊断为原发性高血压的患者68例,其中男性34例,女性34例。年龄47.4±8岁;病程10.5±8年。属Ⅰ期29例,Ⅱ期39
Perindopril (Acertil) is a novel angiotensin-converting enzyme inhibitor that does not contain sulfhydryl. This article aims to evaluate the goods for the treatment of hypertensive patients in our clinical efficacy and tolerance. 1 Materials and Methods ① Case Selection: According to WHO (1978) criteria for the diagnosis of essential hypertension in 68 patients, including 34 males and 34 females. Age 47.4 ± 8 years; duration of 10.5 ± 8 years. It belongs to stage Ⅰ in 29 cases and stage Ⅱ